Geron (GERN) Stock: Buy, Sell, or Hold?
GERN - Geron Corp
$1.35
-0.02 (-1.46%)
▼
5d:
-10.6%
30d:
-14.01%
90d:
+18.42%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 3, 2026 at $1.53 · last confirmed Sep 11, 2026
Strength: 8.0/10
Get Alerted When GERN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GERN is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GERN is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GERN is currently trading at $1.35, which is considered oversold relative to its 30-day fair value range of $1.42 to $1.59. From a valuation perspective, the stock is trading at a premium (Forward PE: 33.8) compared to its historical average (23.8). At these levels, the market is pricing in 12.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GERN is in a downtrend. The price is currently testing key support at $1.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GERN scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.25 (+214.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GERN is in a downtrend. The price is currently testing key support at $1.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GERN scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.25 (+214.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.42 -
$1.59
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
56.2%
Protect Your Profits
Holding GERN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 214.8% below Wall St target ($4.25)
- NEUTRAL: Trading at premium valuation - market expects 12.3% growth which is achievable
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.42 -
$1.59
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.34
Resistance Level
$1.62
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
33.75
Wall Street Target
$4.25
(+214.8%)
Revenue Growth (YoY)
17.2%
Profit Margin
-33.1%
Valuation Premium vs History
+12.3% premium
PE vs Historical
33.8 vs 23.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.3%
(market-implied from PE analysis)
1-Year Target
$1.52
(+12%)
2-Year Target
$1.70
(+26%)
3-Year Target
$1.91
(+42%)
3-Yr Target (if PE normalizes)
(PE: 34→24)
PE COMPRESSION
$1.35
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: September 12, 2026 2:06 PM ET
Data refreshes hourly during market hours. Next update: 3:06 PM
Data refreshes hourly during market hours. Next update: 3:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GERN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
LRMR
Larimar Therapeutics Inc |
STRONG BUY
11 analysts |
$14 | 58 HOLD |
Advanced GERN Option Strategies
Professional options setups generated by AI based on today's GERN price and gamma walls.
